Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

被引：0
|
作者：
Tim Heise
Leo Seman
Sreeraj Macha
Peter Jones
Alexandra Marquart
Sabine Pinnetti
Hans J. Woerle
Klaus Dugi
机构：
[1] Profil Institut für Stoffwechselforschung GmbH,
[2] Boehringer Ingelheim Pharmaceuticals,undefined
[3] Inc.,undefined
[4] With Confidence Ltd.,undefined
[5] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[6] Boehringer Ingelheim Pharma GmbH & Co. KG,undefined
[7] Boehringer Ingelheim GmbH,undefined
来源：
Diabetes Therapy | 2013年 / 4卷
关键词：
BI 10773; Diabetes; Empagliflozin; Pharmacodynamics; Pharmacokinetics; Safety; Tolerability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：331 / 345
页数：14
相关论文
共 50 条
  • [31] Liraglutide trial in paediatric subjects with type 2 diabetes: safety, tolerability and pharmacokinetics/pharmacodynamics
    Battelino, T.
    Klein, D.
    Chatterjee, D. J.
    Hale, P.
    Chang, C. T.
    Arslanian, S.
    DIABETOLOGIA, 2012, 55 : S7 - S7
  • [32] Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
    Retlich, Silke
    Duval, Vincent
    Graefe-Mody, Ulrike
    Friedrich, Christian
    Patel, Sanjay
    Jaehde, Ulrich
    Staab, Alexander
    CLINICAL PHARMACOKINETICS, 2015, 54 (07) : 737 - 750
  • [33] Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus
    Silke Retlich
    Vincent Duval
    Ulrike Graefe-Mody
    Christian Friedrich
    Sanjay Patel
    Ulrich Jaehde
    Alexander Staab
    Clinical Pharmacokinetics, 2015, 54 : 737 - 750
  • [34] Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects
    Yamahira, Naomi
    Frost, Charles
    Fukase, Hiroyuki
    Yu, Zhigang
    Wang, Jessie
    Pursley, Janice
    LaCreta, Frank
    Hiraoka, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2014, 52 (07) : 564 - 573
  • [35] Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of the Novel Dual GIP/GLP-1 Agonist RG7697 in Patients with Type 2 Diabetes Mellitus
    Schmitt, Christophe
    Portron, Agnes
    Jadidi, Shirin
    Sarkar, Neena
    Dimarchi, Richard
    DIABETES, 2017, 66 : A290 - A290
  • [36] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A302 - A303
  • [37] Exenatide in adolescent patients with type 2 diabetes: Pharmacokinetics, pharmacodynamics, safety, and
    Malloy, Jaret
    Guan, Xuesong
    Kothare, Prajakti.
    Capparelli, Edmund
    Fineman, Mark
    DIABETES, 2008, 57 : A145 - A145
  • [38] Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus
    Zhou, Chen
    Zhou, Sufeng
    Wang, Jie
    Xie, Lijun
    Lv, Zhanhui
    Zhao, Yuqing
    Wang, Lu
    Luo, Huan
    Xie, Daosheng
    Shao, Feng
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [39] Pharmacokinetics, pharmacodynamics, safety and tolerability of pramlintide in adolescent subjects with type 1 diabetes
    Lorenzi, G.
    Chase, P.
    Zhang, B.
    Pencek, R.
    Lutz, K.
    DIABETOLOGIA, 2008, 51 : S408 - S408
  • [40] Pharmacokinetics, pharmacodynamics, safety and tolerability of pramlintide in adolescent subjects with type 1 diabetes
    Chase, Peter
    Zhang, Bei
    Pencek, Richard
    Lutz, Karen
    DIABETES, 2008, 57 : A500 - A500
12345